E2082 0047
Alternative Names: E2082-0047Latest Information Update: 11 Mar 2024
At a glance
- Originator Eilean Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Acute myeloid leukaemia
Most Recent Events
- 09 Dec 2023 Clinical trials in Acute myeloid leukaemia (In volunteers) (unspecified route)
- 09 Dec 2023 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route) prior to December 2023
- 09 Dec 2023 Adverse events and pharmacodynamics data from a preclinical trial in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)